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In the previous issue of Critical Care, Derwall and 
colleagues [1] reported on the eﬀ  ects of gaseous hydrogen 
sulﬁ  de (H2S) (100 to 300 parts per million) in healthy, 
anesthetized, and mechanically ventilated sheep. To 
avoid any airway irritation, the authors used an elegant 
approach to circumvent inhaling H2S (that is, adminis-
tration via an extracorporeal, veno-arterial membrane 
oxygenator). Th   e major ﬁ  ndings were that (a) whole body 
oxygen uptake (VO2), carbon dioxide production (VCO2), 
and cardiac output remained within the physiological 
range but that (b) H2S caused pulmonary vasocon  stric-
tion, which was (c) associated with a fall in blood pressure 
and metabolic acidosis at the highest doses administered.
In a landmark paper, Blackstone and colleagues [2] 
demonstrated that, in awake, spontaneously breathing 
mice, inhaling H2S induced a hibernation-like metabolic 
state characterized by reduced energy expenditure and 
hypothermia. Subsequently, Volpato and colleagues [3] 
reported that this metabolic depression was associated 
with bradycardia and reduced cardiac output but that 
blood pressure and stroke volume remained unaﬀ  ected. 
Consequently, given the exciting prospect of pharma  co-
logically reducing energy expenditure to protect against 
ischemia (‘suspended animation’ [2]) by application of a 
gaseous drug, the eﬀ  ects of inhaled H2S were investigated 
in various models. In fact, inhaled H2S protected rodents 
against other  wise lethal hypoxia [4] and hemorrhage [5] 
and attenuated murine kidney and lung injury [6-8]. 
Equivocal data, however, are available from large animals: 
inhaled H2S failed to show any metabolic eﬀ  ect in sheep 
or swine [9,10], and the intravenous H2S donor sodium 
sulﬁ  de  (Na2S) was reported either to reduce energy 
expenditure [11] or to have no eﬀ  ect at all [12].
What do we learn from the study by Derwall and 
colleagues [1]? Th   e authors conﬁ  rm previous data in the 
same species [9] that even a ﬁ  vefold-higher concentration 
of inhaled H2S did not depress energy expenditure. Since 
the authors maintained the body temperature, they 
speculate that in larger species H2S can hardly aﬀ  ect 
metabolism at all beyond the eﬀ  ect of temperature per se 
(the ‘Q10 eﬀ  ect’: the fall of VO2 and VCO2 associated 
with a 10°C decrease), in particular when metabolism is 
already depressed. In fact, in anesthetized and mecha  ni-
cally ventilated mice subjected to deliberate hypothermia, 
inhaled H2S had no further metabolic and circulatory 
eﬀ   ects [13]. Moreover, in larger adult animals, non-
shivering thermogenesis is negligible and thus can  not be 
inﬂ  uenced such as in small animals (for example, mice) 
with a metabolic rate that is 15- to 20-fold higher than 
that of humans [9]. Finally, any Na2S-related thera  peutic 
eﬀ  ect in larger animals was independent of body tem-
pera ture  [14-16].
Abstract
Whether the hydrogen sulfi  de (H2S)-induced metabolic 
depression observed in awake rodents exists in 
larger species is controversial. Therefore, Derwall and 
colleagues exposed anesthetized and ventilated 
sheep to incremental H2S concentrations by means 
of an extracorporeal membrane oxygenator. H2S 
caused pulmonary vasoconstriction and metabolic 
acidosis at the highest concentration studied. Oxygen 
uptake and carbon dioxide production remained in 
the physiological range. The authors concluded that, 
beyond the eff  ect of temperature, H2S hardly modifi  es 
metabolism at all. Since the highest H2S concentration 
caused toxic side eff  ects (possibly due to an inhibition 
of mitochondrial respiration), the therapeutic use of 
inhaled H2S should be cautioned.
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© 2011 BioMed Central LtdWhat is the future of H2S in critical care medicine? Th  e 
vascular eﬀ  ects of H2S are still controversial: Derwall and 
colleagues [1] found a dose-dependent pulmonary vaso-
con  striction, which at ﬁ  rst glance agrees with the hypoxia-
sensing properties attributed to H2S [17]. However, the 
mixed venous oxygen partial pressure (PO2) was 50 to 
55 mm Hg (that is, clearly above the range that induced 
hypoxic vasoconstriction of isolated pulmonary arteries 
of cows [17]). In addition, the pulmonary vascular vaso-
motor response to H2S  in vitro showed marked inter-
species diﬀ  erences, so that any eﬀ  ect in the critically ill 
patient is diﬃ   cult to anticipate [17]. Th   e systemic vaso-
motor eﬀ  ect of H2S is equally intriguing: endogenous H2S 
is a physiological vasodilator and thus assumes major 
importance in the control of blood pressure [18]. Derwall 
and colleagues [1] report that the highest H2S concen  tra-
tion caused marked systemic vasodilation, whereas other 
authors [11,16] found that Na2S reduced the noradrena-
line doses required to achieve hemodynamic targets 
during reperfusion after porcine aortic balloon occlusion.
Th  e appropriate H2S dose is also unknown: in the 
previous large animal studies, a 25-fold range of intra-
venous Na2S infusion rates was used [11,12,14-16], and, 
as in the present investigation, higher infusion rates over 
longer periods of time impaired pulmonary gas exchange 
[11,12]. Th  e  signiﬁ  cant meta  bolic acidosis aﬃ   liated with 
the highest H2S concentra  tion deserves particular 
attention, but unfortunately the authors did not further 
elucidate this ﬁ   nding. It is tempting to speculate that 
inhibition of mitochodondrial respiration with subse-
quent reduction of aerobic capacity caused this metabolic 
acidosis: H2S is a well-established inhibitor of the cyto-
chrome C oxidase, and the subtle increase in the respira-
tory quotient that can be derived from the mean VO2 and 
VCO2 values before and after exposure to 300 parts per 
million H2S, respectively, replicates data reported on the 
eﬀ   ects of H2S inhalation in exercising humans [19]. 
Finally, as the authors themselves acknowledge, the fate 
of exogenous H2S remains unclear: they found, in the 
eﬀ   erent blood of the extracorporeal membrane lung, 
sulﬁ   de levels that were associated with near-complete 
inhibition of the respira  tory chain in vitro [13]. Th  e 
arterial blood concentrations, however, were in the same 
range as measured during Na2S infusion in swine, in 
which Na2S protected against myocardial [16] and renal 
[17] ischemia/reperfusion injury.
In conclusion, Derwall and colleagues performed an 
elegant ovine study to test whether a pharmacological 
(that is, H2S-induced) metabolic depression can be 
achieved in large animals. While the authors did not ﬁ  nd 
any gross modiﬁ   cations of energy expenditure, they 
observed several intriguing hemodynamic and acid-base 
eﬀ  ects, which conﬁ  rm the complex actions of this ‘third 
gaseous mediator’.
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